Wei Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Jiang has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Zhenming Hu
Department of Orthopedics, University-Town Hospital of Chongqing Medical University, Chongqing, China
4 shared publications - Jie Hao
Department of Orthopaedic Surgery, Chongqing Municipal Health Commission Key Laboratory of Musculoskeletal Regeneration and Translational Medicine/Orthopaedic Research Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications Xiaojun Zhang
Department of Orthopaedic Surgery, Chongqing Municipal Health Commission Key Laboratory of Musculoskeletal Regeneration and Translational Medicine/Orthopaedic Research Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publicationsBin Yu
Department of Radiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
1 shared publicationBo Sheng
Department of Radiology The First Affiliated Hospital of Chongqing Medical University Chongqing 400016 China cqmu.edu.cn
1 shared publicationChanghai Jiang
Department of Orthopedics, The People’s Hospital of Chuxiong Yi Autonomous Prefecture, Chuxiong, Yunnan, China
1 shared publication
Latest Publications
- Open Access
- 24 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Intradiscal platelet-rich plasma for discogenic low back pain: a prospective cohort study of early clinical outcomes and quantitative MRI findings
Discogenic low back pain (DLBP) is a major cause of disability. Platelet-rich plasma (PRP) has shown regenerative potential in preclinical models, but clinical results remain heterogeneous and early biological responses in humans are incompletely understood. We conducted a prospective cohort study (November 2023–October 2024) to evaluate early clinical outcomes and quantitative MRI (qMRI) changes after intradiscal PRP injection for DLBP. Symptom scores (VAS, ODI and FRI) and qMRI measures (whole-disc T2 and vertebral marrow fat fraction in adjacent vertebrae) were assessed at baseline and at 1, 3 and 6 months. A composite minimal clinically important difference (MCID) was predefined as a ≥ 30% reduction from baseline in both VAS and ODI. Longitudinal changes were analyzed using linear mixed-effects models, and baseline-to-6-month changes were correlated using Pearson tests. Forty-five patients were recruited and 29 completed follow-up. VAS, ODI and FRI decreased significantly over time (all P < 0.001), and 79.3% achieved the composite MCID at 6 months. Vertebral marrow fat fraction adjacent to the treated disc declined significantly (P < 0.001) and correlated with improvements in VAS, ODI and FRI (r ≈ 0.46–0.56; P < 0.01), whereas changes in whole-disc T2 were small and not associated with symptom change. No treatment-related complications were observed. Intradiscal PRP appeared safe and clinically promising over 6 months, with qMRI suggesting an early effect on the peridiscal metabolic environment.
- 24 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIntradiscal platelet-rich plasma for discogenic low back pain: a prospective cohort study of early clinical outcomes and quantitative MRI findings
Discogenic low back pain (DLBP) is a major cause of disability. Platelet-rich plasma (PRP) has shown regenerative potential in preclinical models, but clinical results remain heterogeneous and early biological responses in humans are incompletely understood. We conducted a prospective cohort study (November 2023–October 2024) to evaluate early clinical outcomes and quantitative MRI (qMRI) changes after intradiscal PRP injection for DLBP. Symptom scores (VAS, ODI and FRI) and qMRI measures (whole-disc T2 and vertebral marrow fat fraction in adjacent vertebrae) were assessed at baseline and at 1, 3 and 6 months. A composite minimal clinically important difference (MCID) was predefined as a ≥ 30% reduction from baseline in both VAS and ODI. Longitudinal changes were analyzed using linear mixed-effects models, and baseline-to-6-month changes were correlated using Pearson tests. Forty-five patients were recruited and 29 completed follow-up. VAS, ODI and FRI decreased significantly over time (all P < 0.001), and 79.3% achieved the composite MCID at 6 months. Vertebral marrow fat fraction adjacent to the treated disc declined significantly (P < 0.001) and correlated with improvements in VAS, ODI and FRI (r ≈ 0.46–0.56; P < 0.01), whereas changes in whole-disc T2 were small and not associated with symptom change. No treatment-related complications were observed. Intradiscal PRP appeared safe and clinically promising over 6 months, with qMRI suggesting an early effect on the peridiscal metabolic environment.
- Open Access
- 13 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (7) , e47627
The causal relationship between immune cells and both seropositive and seronegative rheumatoid arthritis: A bidirectional Mendelian randomization study
Rheumatoid arthritis (RA) is a chronic, immune-mediated disease with symmetric polyarticular pain and swelling. It includes seropositive RA, marked by specific antibodies, and seronegative RA, without these antibodies. The relationship between immune cells and both types of RA has not been fully elucidated. Therefore, we conducted a two-sample Mendelian randomization analysis with bidirection to evaluate the causal relationship between immune cells and both seropositive and seronegative RA. We utilized data from various genome-wide association studies and employed multiple analytical methods, including inverse-variance weighted and Wald ratio, as the primary method. Additionally, we employed supplementary approaches such as MR-Egger regression, weighted median, and weighted mode. Various sensitivity analyses were used to ensure the robustness of our results. Furthermore, we utilized the false discovery rate method to mitigate type 1 error. We identified 3 immune cell types linked to higher seropositive RA risk, and 16 immune cell types might be influenced by seronegative RA (4 increased and 12 decreased). Notably, HLA-DR + monocytes were strongly associated with seropositive RA, while changes in immune cell composition in seronegative RA suggest potential biomarkers for its diagnosis. These findings offer valuable insights into RA pathogenesis and highlight the potential for novel diagnostic and therapeutic strategies, particularly for seronegative RA, which lacks reliable biomarkers. Further research is needed to explore the underlying mechanisms and their clinical applications.
- 13 February 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (7) , e47627
Open AccessThe causal relationship between immune cells and both seropositive and seronegative rheumatoid arthritis: A bidirectional Mendelian randomization study
Rheumatoid arthritis (RA) is a chronic, immune-mediated disease with symmetric polyarticular pain and swelling. It includes seropositive RA, marked by specific antibodies, and seronegative RA, without these antibodies. The relationship between immune cells and both types of RA has not been fully elucidated. Therefore, we conducted a two-sample Mendelian randomization analysis with bidirection to evaluate the causal relationship between immune cells and both seropositive and seronegative RA. We utilized data from various genome-wide association studies and employed multiple analytical methods, including inverse-variance weighted and Wald ratio, as the primary method. Additionally, we employed supplementary approaches such as MR-Egger regression, weighted median, and weighted mode. Various sensitivity analyses were used to ensure the robustness of our results. Furthermore, we utilized the false discovery rate method to mitigate type 1 error. We identified 3 immune cell types linked to higher seropositive RA risk, and 16 immune cell types might be influenced by seronegative RA (4 increased and 12 decreased). Notably, HLA-DR + monocytes were strongly associated with seropositive RA, while changes in immune cell composition in seronegative RA suggest potential biomarkers for its diagnosis. These findings offer valuable insights into RA pathogenesis and highlight the potential for novel diagnostic and therapeutic strategies, particularly for seronegative RA, which lacks reliable biomarkers. Further research is needed to explore the underlying mechanisms and their clinical applications.
- Open Access
- 3 July 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1418393
Sugar-sweetened beverage intake and chronic low back pain
Background: The consumption of sugar-sweetened beverages (SSBs) has become a major public health problem globally. However, no studies have specifically examined the relationship between SSB intake and chronic low back pain (CLBP). Therefore, the present study aimed to investigate the relationship between SSB intake and the risk of CLBP.Methods: This cross-sectional study enrolled participants aged 20 to 69 from the National Health and Nutrition Examination Survey. CLBP was defined as persistent LBP for a consecutive three-month period. Furthermore, SSB intake was assessed and calculated based on dietary recall interviews. Moreover, survey-weighted logistic regression models were employed to evaluate the association between SSB intake and the risk of CLBP, while the restricted cubic spline (RCS) analysis was used to determine whether there were nonlinear associations between SSB intake and CLBP risk. In addition, subgroup analysis was performed using stratification and interaction analysis for all covariates.Results: A total of 4,146 participants (mean age: 43.405 years) were enrolled in the final analysis. The results of survey-weighted logistic regression models showed that SSB consumption was significantly associated with an increased risk of CLBP among individuals aged 20 to 69 years. Moreover, the results of subgroup analysis and interaction analysis demonstrated that the association between SSB intake and the risk of CLBP was modified by smoking status and hypertension. Specifically, the SSB intake-associated CLBP risk was more pronounced among current smokers or individuals with hypertension.Conclusion: Reduction of SSB consumption might contribute to the prevention of CLBP for individuals aged 20 to 69 years. Moreover, current smokers or individuals with hypertension should be more vigilant about the SSB intake-associated CLBP risk. Nevertheless, caution should be exercised when interpreting the results of this study, as further research is necessary to explore the association between SSB consumption and CLBP, given the limitations of the current study.
- 3 July 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1418393
Open AccessSugar-sweetened beverage intake and chronic low back pain
Background: The consumption of sugar-sweetened beverages (SSBs) has become a major public health problem globally. However, no studies have specifically examined the relationship between SSB intake and chronic low back pain (CLBP). Therefore, the present study aimed to investigate the relationship between SSB intake and the risk of CLBP.Methods: This cross-sectional study enrolled participants aged 20 to 69 from the National Health and Nutrition Examination Survey. CLBP was defined as persistent LBP for a consecutive three-month period. Furthermore, SSB intake was assessed and calculated based on dietary recall interviews. Moreover, survey-weighted logistic regression models were employed to evaluate the association between SSB intake and the risk of CLBP, while the restricted cubic spline (RCS) analysis was used to determine whether there were nonlinear associations between SSB intake and CLBP risk. In addition, subgroup analysis was performed using stratification and interaction analysis for all covariates.Results: A total of 4,146 participants (mean age: 43.405 years) were enrolled in the final analysis. The results of survey-weighted logistic regression models showed that SSB consumption was significantly associated with an increased risk of CLBP among individuals aged 20 to 69 years. Moreover, the results of subgroup analysis and interaction analysis demonstrated that the association between SSB intake and the risk of CLBP was modified by smoking status and hypertension. Specifically, the SSB intake-associated CLBP risk was more pronounced among current smokers or individuals with hypertension.Conclusion: Reduction of SSB consumption might contribute to the prevention of CLBP for individuals aged 20 to 69 years. Moreover, current smokers or individuals with hypertension should be more vigilant about the SSB intake-associated CLBP risk. Nevertheless, caution should be exercised when interpreting the results of this study, as further research is necessary to explore the association between SSB consumption and CLBP, given the limitations of the current study.
- Open Access
- 11 January 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (4) , 2122-2133
The effect of perioperative sequential application of multiple doses of tranexamic acid on postoperative blood loss after PLIF: a prospective randomized controlled trial
Background: Tranexamic acid (TXA) has been utilized in spinal surgery to effectively reduce intraoperative blood loss (IBL) and allogeneic blood transfusion rates. However, the traditional TXA regimen might last the entire duration of hyperfibrinolysis caused by surgical trauma, resulting in its limited ability to reduce postoperative blood loss (PBL). Therefore, the aim of this study was to investigate the effectiveness of perioperative sequential administration of multiple doses of TXA in reducing PBL in patients who underwent posterior lumbar interbody fusion (PLIF). Methods: From October 2022 to June 2023, 231 patients who were diagnosed with lumbar degenerative disease and scheduled to undergo PLIF were prospectively enrolled in the present study. The patients were randomly divided into three groups. Moreover, all patients received an intravenous injection of TXA at a dose of 15 mg/kg 15 min before the surgical skin incision. Patients in Group A received a placebo of normal saline after surgery, while patients in Group B received three additional intravenous injections of TXA at a dose of 15 mg/kg every 24 h. Patients in Group C received three additional intravenous injections of TXA at a dose of 15 mg/kg every 5 h. The primary outcome measure was PBL. In addition, this study assessed total blood loss (TBL), IBL, routine blood parameters, liver and kidney function, coagulation parameters, fibrinolysis indexes, inflammatory indicators, drainage tube removal time (DRT), length of hospital stay (LOS), blood transfusion rate, and incidence of complications for all subjects. Results: The PBL, TBL, DRT, and LOS of Group B and Group C were significantly lower than those of Group A (P Group B > Group C. No serious complications were observed in any patient. The results of multiple stepwise linear regression analysis revealed that PBL was positively correlated with incision length, IBL, smoking history, history of hypertension, preoperative fibrinogen degradation product level, and blood transfusion. It was negatively correlated with preoperative levels of fibrinogen, red blood cells, blood urea nitrogen, and age. Compared to female patients, male patients had an increased risk of PBL. Finally, the incidence of PBL was predicted. Conclusions: Sequential application of multiple doses of TXA during the perioperative period could safely and effectively reduce PBL and TBL, shorten DRT and LOS, reduce postoperative D-D generation, and reduce the postoperative inflammatory response. In addition, this study provided a novel prediction model for PBL in patients undergoing PLIF.
- 11 January 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (4) , 2122-2133
Open AccessThe effect of perioperative sequential application of multiple doses of tranexamic acid on postoperative blood loss after PLIF: a prospective randomized controlled trial
Background: Tranexamic acid (TXA) has been utilized in spinal surgery to effectively reduce intraoperative blood loss (IBL) and allogeneic blood transfusion rates. However, the traditional TXA regimen might last the entire duration of hyperfibrinolysis caused by surgical trauma, resulting in its limited ability to reduce postoperative blood loss (PBL). Therefore, the aim of this study was to investigate the effectiveness of perioperative sequential administration of multiple doses of TXA in reducing PBL in patients who underwent posterior lumbar interbody fusion (PLIF). Methods: From October 2022 to June 2023, 231 patients who were diagnosed with lumbar degenerative disease and scheduled to undergo PLIF were prospectively enrolled in the present study. The patients were randomly divided into three groups. Moreover, all patients received an intravenous injection of TXA at a dose of 15 mg/kg 15 min before the surgical skin incision. Patients in Group A received a placebo of normal saline after surgery, while patients in Group B received three additional intravenous injections of TXA at a dose of 15 mg/kg every 24 h. Patients in Group C received three additional intravenous injections of TXA at a dose of 15 mg/kg every 5 h. The primary outcome measure was PBL. In addition, this study assessed total blood loss (TBL), IBL, routine blood parameters, liver and kidney function, coagulation parameters, fibrinolysis indexes, inflammatory indicators, drainage tube removal time (DRT), length of hospital stay (LOS), blood transfusion rate, and incidence of complications for all subjects. Results: The PBL, TBL, DRT, and LOS of Group B and Group C were significantly lower than those of Group A (P Group B > Group C. No serious complications were observed in any patient. The results of multiple stepwise linear regression analysis revealed that PBL was positively correlated with incision length, IBL, smoking history, history of hypertension, preoperative fibrinogen degradation product level, and blood transfusion. It was negatively correlated with preoperative levels of fibrinogen, red blood cells, blood urea nitrogen, and age. Compared to female patients, male patients had an increased risk of PBL. Finally, the incidence of PBL was predicted. Conclusions: Sequential application of multiple doses of TXA during the perioperative period could safely and effectively reduce PBL and TBL, shorten DRT and LOS, reduce postoperative D-D generation, and reduce the postoperative inflammatory response. In addition, this study provided a novel prediction model for PBL in patients undergoing PLIF.
- 19 August 2023
- Published by Tsinghua University Press in Nano Research
- Vol. 17 (3) , 1772-1784
ZIF-8 coated gold nanospheres: a multi-responsive drug delivery system promoting the killing effect of photothermal therapy against osteosarcoma cells
Photothermal therapy (PTT) has been widely used in the treatment of tumors, but its efficacy is greatly limited by the inability of precise drug delivery and the increase of heat shock proteins (HSPs) caused by high temperature. This article describes a therapeutic strategy to enhance PTT with starvation therapy in conjunction with ferroptosis mechanism. A nanoparticle platform ZIF-8@GA was constructed by wrapping together glucose oxidase (GOX) and gold nanospheres (AuNPs) loaded with dihydroartemisinin (DHA) with zeolitic imidazolate framework-8 (ZIF-8). This platform can take advantage of the micro-environment of osteosarcoma (OS) cells, featuring low pH and high reactive oxygen species (ROS), for precision drug delivery. GOX can effectively catalyze glucose to produce gluconic acid and H2O2, and DHA can also induce ROS production in OS cells. ROS produced by GOX and DHA can further generate lipid peroxidation (LPO) and lead to ferroptosis of OS cells. At the same time, ROS and LPO produced can inhibit the expression of HSPs, thereby increasing the therapeutic effect of PTT. In vitro experiments show that the nanoparticles are pH and ROS responsive. 1 µg/mL GOX combined with 0.2 µg/mL DHA promotes ferroptosis of OS cells, and increases the killing effect of near-infrared (NIR) on OS cells. Further in vivo experiments showed that the nano drug-delivery platform combined with PTT can effectively inhibit the growth of OS cells. Meanwhile, this study provides a new idea for the treatment of OS with biomaterials combined with various treatment methods.
- 19 August 2023
- Published by Tsinghua University Press in Nano Research
- Vol. 17 (3) , 1772-1784
ZIF-8 coated gold nanospheres: a multi-responsive drug delivery system promoting the killing effect of photothermal therapy against osteosarcoma cells
Photothermal therapy (PTT) has been widely used in the treatment of tumors, but its efficacy is greatly limited by the inability of precise drug delivery and the increase of heat shock proteins (HSPs) caused by high temperature. This article describes a therapeutic strategy to enhance PTT with starvation therapy in conjunction with ferroptosis mechanism. A nanoparticle platform ZIF-8@GA was constructed by wrapping together glucose oxidase (GOX) and gold nanospheres (AuNPs) loaded with dihydroartemisinin (DHA) with zeolitic imidazolate framework-8 (ZIF-8). This platform can take advantage of the micro-environment of osteosarcoma (OS) cells, featuring low pH and high reactive oxygen species (ROS), for precision drug delivery. GOX can effectively catalyze glucose to produce gluconic acid and H2O2, and DHA can also induce ROS production in OS cells. ROS produced by GOX and DHA can further generate lipid peroxidation (LPO) and lead to ferroptosis of OS cells. At the same time, ROS and LPO produced can inhibit the expression of HSPs, thereby increasing the therapeutic effect of PTT. In vitro experiments show that the nanoparticles are pH and ROS responsive. 1 µg/mL GOX combined with 0.2 µg/mL DHA promotes ferroptosis of OS cells, and increases the killing effect of near-infrared (NIR) on OS cells. Further in vivo experiments showed that the nano drug-delivery platform combined with PTT can effectively inhibit the growth of OS cells. Meanwhile, this study provides a new idea for the treatment of OS with biomaterials combined with various treatment methods.
- Open Access
- 4 August 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1192971
The effect of sequential perioperative intravenous tranexamic acid in reducing postoperative blood loss and hidden blood loss after posterior lumbar interbody fusion: a randomized controlled trial
Background: Tranexamic acid (TXA) has previously been shown to be effective in reducing intraoperative blood loss (IBL) and transfusion requirements in spine surgery. A conventional TXA regimen is a simple preoperative or intraoperative administration. However, the hyperfibrinolysis caused by surgical trauma lasts at least 24 h, and a single dose of TXA cannot cover the whole process of hyperfibrinolysis. Moreover, its ability to control postoperative blood loss (PBL) may be insufficient. Therefore, this study aimed to explore the effects and safety of sequential perioperative intravenous TXA for reducing bleeding after posterior lumbar interbody fusion (PLIF).Methods: Patients requiring PLIF were randomly divided into two groups. All patients were intravenously injected with 1 g of TXA 15 min before skin resection. Every day after the surgery, 200 ml saline was intravenously injected for 1–3 days in Group A, while Group B received 1 g of TXA instead of saline. The total blood loss (TBL), IBL, PBL, HCT, Hb, blood transfusion volume, inflammation-related indicators, and complications were recorded.Results: TBL, PBL, and hidden blood loss (HBL) in Group B were significantly lower than those in Group A (P < 0.05). The maximum decreases in HCT and Hb in Group B were also significantly lower than those in Group A (P < 0.05), and the drainage removal time (DRT) was sooner in Group B than in Group A (P = 0.003). On the 3rd and 5th days after surgery, the level of CRP in Group B was significantly lower than that in Group A (P < 0.05). Similarly, IL-6 levels were significantly lower in Group B for the first 5 days postoperatively (P < 0.001). Sex, operation time, level of decompression, length of incision, and change in HCT were significant predictors of both TBL and HBL. TBL was also significantly associated with BMI and preoperative fibrinogen, while postoperative TXA was a significant predictor of HBL only.Conclusion: Intravenous injection of 1 g of TXA 15 min before skin resection combined with continuous intravenous injection of 1 g of TXA 1 to 3 days after PLIF can reduce postoperative bleeding and shorten the time to drainage tube removal. In addition, it can also inhibit the postoperative inflammatory response.Clinical trial registration: ChiCTR2200056210.
- 4 August 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1192971
Open AccessThe effect of sequential perioperative intravenous tranexamic acid in reducing postoperative blood loss and hidden blood loss after posterior lumbar interbody fusion: a randomized controlled trial
Background: Tranexamic acid (TXA) has previously been shown to be effective in reducing intraoperative blood loss (IBL) and transfusion requirements in spine surgery. A conventional TXA regimen is a simple preoperative or intraoperative administration. However, the hyperfibrinolysis caused by surgical trauma lasts at least 24 h, and a single dose of TXA cannot cover the whole process of hyperfibrinolysis. Moreover, its ability to control postoperative blood loss (PBL) may be insufficient. Therefore, this study aimed to explore the effects and safety of sequential perioperative intravenous TXA for reducing bleeding after posterior lumbar interbody fusion (PLIF).Methods: Patients requiring PLIF were randomly divided into two groups. All patients were intravenously injected with 1 g of TXA 15 min before skin resection. Every day after the surgery, 200 ml saline was intravenously injected for 1–3 days in Group A, while Group B received 1 g of TXA instead of saline. The total blood loss (TBL), IBL, PBL, HCT, Hb, blood transfusion volume, inflammation-related indicators, and complications were recorded.Results: TBL, PBL, and hidden blood loss (HBL) in Group B were significantly lower than those in Group A (P < 0.05). The maximum decreases in HCT and Hb in Group B were also significantly lower than those in Group A (P < 0.05), and the drainage removal time (DRT) was sooner in Group B than in Group A (P = 0.003). On the 3rd and 5th days after surgery, the level of CRP in Group B was significantly lower than that in Group A (P < 0.05). Similarly, IL-6 levels were significantly lower in Group B for the first 5 days postoperatively (P < 0.001). Sex, operation time, level of decompression, length of incision, and change in HCT were significant predictors of both TBL and HBL. TBL was also significantly associated with BMI and preoperative fibrinogen, while postoperative TXA was a significant predictor of HBL only.Conclusion: Intravenous injection of 1 g of TXA 15 min before skin resection combined with continuous intravenous injection of 1 g of TXA 1 to 3 days after PLIF can reduce postoperative bleeding and shorten the time to drainage tube removal. In addition, it can also inhibit the postoperative inflammatory response.Clinical trial registration: ChiCTR2200056210.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
SIRT1 Inhibits Apoptosis by Promoting Autophagic Flux in Human Nucleus Pulposus Cells in the Key Stage of Degeneration via ERK Signal Pathway
Background. The application of biomolecular interventions in the early stage of intervertebral disc degeneration (IVDD) is considered an ideal method for the treatment of IVDD. However, the precise definition of the “early stage” of IVDD is unclear. Silent information regulation 2 homologue‐1 (SIRT1) can protect human degenerative nucleus pulposus (NP) cells from apoptosis by activating autophagy. However, the mechanism of this effect is still unclear. This study tried to confirm the “early stage” of IVDD and the role of NP cell autophagy during IVDD as well as to determine the mechanism by which SIRT1 protects NP cells. Methods. The characteristics of the NP in various stages of degeneration were assessed to confirm the “early stage” of IVDD. Then, autophagy and apoptosis were detected in NP cells after SIRT1 upregulation/downregulation. Finally, LY294002 and PD98059 were used to inhibit the AKT/ERK pathway to determine the mechanism by which SIRT1 regulates autophagy in NP cells. Results. Our data showed that mildly degenerative (Pfirrmann grade III with normal height of intervertebral disc) NP cells may be the key target for biomolecular interventions in IVDD and that SIRT1 protects human mildly degenerative NP cells from apoptosis by activating autophagy via the ERK signalling pathway. Conclusion. Our data showed that SIRT1 inhibits apoptosis by promoting the autophagic flux in NP cells via the ERK signalling pathway during the key stage of degeneration. These findings will assist in the development of novel therapeutic approaches for IVDD treatment.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessSIRT1 Inhibits Apoptosis by Promoting Autophagic Flux in Human Nucleus Pulposus Cells in the Key Stage of Degeneration via ERK Signal Pathway
Background. The application of biomolecular interventions in the early stage of intervertebral disc degeneration (IVDD) is considered an ideal method for the treatment of IVDD. However, the precise definition of the “early stage” of IVDD is unclear. Silent information regulation 2 homologue‐1 (SIRT1) can protect human degenerative nucleus pulposus (NP) cells from apoptosis by activating autophagy. However, the mechanism of this effect is still unclear. This study tried to confirm the “early stage” of IVDD and the role of NP cell autophagy during IVDD as well as to determine the mechanism by which SIRT1 protects NP cells. Methods. The characteristics of the NP in various stages of degeneration were assessed to confirm the “early stage” of IVDD. Then, autophagy and apoptosis were detected in NP cells after SIRT1 upregulation/downregulation. Finally, LY294002 and PD98059 were used to inhibit the AKT/ERK pathway to determine the mechanism by which SIRT1 regulates autophagy in NP cells. Results. Our data showed that mildly degenerative (Pfirrmann grade III with normal height of intervertebral disc) NP cells may be the key target for biomolecular interventions in IVDD and that SIRT1 protects human mildly degenerative NP cells from apoptosis by activating autophagy via the ERK signalling pathway. Conclusion. Our data showed that SIRT1 inhibits apoptosis by promoting the autophagic flux in NP cells via the ERK signalling pathway during the key stage of degeneration. These findings will assist in the development of novel therapeutic approaches for IVDD treatment.
- 1 August 2019
- Published by Elsevier in Brain and Development
- Vol. 41 (7) , 614-617
Clinical analysis of psychiatric symptoms of Japanese encephalitis during the convalescent Period: A single center study in Chongqing, China
- 1 August 2019
- Published by Elsevier in Brain and Development
- Vol. 41 (7) , 614-617
Clinical analysis of psychiatric symptoms of Japanese encephalitis during the convalescent Period: A single center study in Chongqing, China